ARMP (Armata Pharmaceuticals) Short Percentage of Float


ARMP Armata Pharmaceuticals Inc ARMP
22 GF Score
Price $7.35
! 3 Warning Signs
View Full Analysis

What is Armata Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ARMP vs SRZN, ELDN, NAGE: Short Percentage of Float Comparison

For the Biotechnology subindustry, Armata Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Armata Pharmaceuticals Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Short Percentage of Float falls into.


ARMP
22GF Score
Armata Pharmaceuticals Inc ARMP
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Armata Pharmaceuticals Business Description

Other Exchanges TG1N:Germany
Address 5005 McConnell Avenue, Los Angeles, CA, USA, 90066
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
22GF Score

Get the complete analysis for ARMP

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.35
Price